iBio(IBIO)
NEW YORK, NYBiotechnology
Focus: iBio is a micro-cap public biotech focused on antibody therapies for oncology and metabolic diseases. With 1–50 employees and minimal commercial revenue ($225K in FY2025), it operates as an early-stage pipeline company in Phase 1 development.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
0
About iBio
AI assessmentNot HiringNo open roles listed right now. Follow iBio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$225K
Pipeline & Clinical Trials
IBIO-600
Overweight , ObesityClinical Trials (1)
NCT07487376A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
Phase 1Help build intelligence for iBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.